following a full submission:
fingolimod (Gilenya®) is accepted for use within NHS Scotland.
Indication under review: as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for the following adult patient groups:
- Patients with high disease activity despite treatment with at least one disease modifying therapy.
In patients who had high disease activity despite prior disease modifying therapy in the previous year, fingolimod reduced the annualised relapse rate compared with another disease modifying therapy.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of fingolimod. This advice is contingent upon the continuing availability of the patient access scheme, or a list price that is equivalent or lower, in NHS Scotland.
Download detailed advice183KB (PDF)
Medicine details
- Medicine name:
- fingolimod (Gilenya)
- SMC ID:
- 1038/15
- Indication:
- As a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for the following adult patient groups: Patients with high disease activity despite treatment with at least one disease modifying therapy.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 April 2015